Celgene (CELG) is one of two firms other than GSK that are considering buying Human Genome...
Sunday, July 8, 2012, 3:00 AM ETCelgene (CELG) is one of two firms other than GSK that are considering buying Human Genome (HGSI) and are holding talks with the company, Reuters reports. There's no word on who the second suitor is, although any deal would most likely be a merger of equals. With Human Genome holding an auction, the deadline for bids is July 16.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles